Watch-and-wait after precision therapy for gastrointestinal cancers
Part of Cancer, Digestive system clinical trials.
This study is looking at whether people with certain gastrointestinal cancers who have had a very good response to targeted therapy or immunotherapy might be able to avoid surgery for now and instead be closely monitored. The goal is to see if this non-surgical approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a gastrointestinal cancer, such as stomach, esophageal, or colorectal cancer.
- Your tumor must have at least one specific genetic marker (like MSI-H, HER2, or others) that can be targeted by special medicines.
- You must have already received a targeted therapy or immunotherapy that matched your tumor's marker and had a very good response (tumor shrank or disappeared).
- A team of doctors must have reviewed your case and agreed that avoiding surgery right away is a reasonable option for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with certain types of gastrointestinal cancers that have a genetic feature called MSI-H/dMMR or POLE mutation. It looks at whether, after immunotherapy, you can avoid surgery or have a less invasive procedure instead, such as watching and waiting, endoscopic removal, or limited surgery.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
This trial is testing a personalized treatment approach for advanced gastric cancer. It uses unique markers in your tumor (HER2, CLDN18.2, PD-L1) to match you with targeted therapies, aiming for better results than standard chemotherapy.
This Phase 2 study tests the best way to choose and then follow treatment when colorectal cancer has spread only to a small number of spots. You may be eligible if your doctors can remove or precisely treat the spots and there’s no sign of additional spread on scans.
This trial compares two approaches for patients with certain types of stomach or colon cancer that have specific genetic features (dMMR, MSI-H, or POLE mutations) and have responded well to immunotherapy: either closely monitoring without surgery, or proceeding with surgery. The goal is to see if some patients can safely avoid surgery while maintaining good outcomes.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.